Key statistics
On Monday, Structure Therapeutics Inc (GPCR:NMQ) closed at 62.90, -33.72% below its 52-week high of 94.90, set on Dec 08, 2025.
52-week range
| Open | 61.88 |
|---|---|
| High | 64.37 |
| Low | 61.51 |
| Bid | 61.00 |
| Offer | 64.00 |
| Previous close | 62.98 |
| Average volume | 768.60k |
|---|---|
| Shares outstanding | 70.84m |
| Free float | 35.44m |
| P/E (TTM) | -- |
| Market cap | 4.46bn USD |
| EPS (TTM) | -2.49 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
- Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
- Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
- Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
- Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants
- Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
- Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
- Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
- Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
- Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
More ▼
